Clinical-stage · Lehi, Utah
Biolexis is developing best-in-class oral GLP-1 receptor agonists and complementary AMPK activators designed to deliver injectable-level efficacy with superior tolerability — engineered from day one for convenient daily dosing and fixed-dose combinations.
4B+
people projected to be overweight or obese by 20381
$100B
projected GLP-1 therapeutics market2
20+
clinical agents discovered by the founding team
$2B+
in transaction value from the founders' prior companies
100+
peer-reviewed publications from the founding science team
The opportunity
01
GLP-1 receptor agonists have unequivocally validated the therapeutic potential of this pathway. They transformed obesity and type 2 diabetes treatment and created a $100B+ market. The clinical and commercial signal is now unambiguous.
02
Patients, payers, and prescribers all want a pill. The bar is real efficacy at oral exposure with a tolerability profile that supports chronic use.
03
The next decade of metabolic medicine will be won by smart combinations. Biolexis is building a mechanistically complementary GLP-1 + AMPK fixed-dose program from a single discovery engine — positioned to deliver superior efficacy, durability, and patient outcomes.
Platform
The same platform that generated our clinical-stage GLP-1 receptor agonist and AMPK activator series is now scaling the next generation of oral metabolic therapies.
Our platform turns decades of hard-won metabolic drug discovery experience into a repeatable, high-precision engine for best-in-class oral assets.
Pipeline
Both lead programs completed Phase 1 with clean safety packages; composition-of-matter IP runway through 2043+.
Lead program · BLX-7006
GI toxicity drives discontinuation → discontinuation drives weight regain → BLX-7006 breaks the chain.
GI-related discontinuation in Phase 1
GLP-1RA real-world discontinuation at 24 months
Weight regained at cessation plateau
Sources: Budini et al. eClinicalMedicine 2026 (in press) · Jaleh et al. J Clin Invest 2026 · Biolexis Phase 1 data (JPM 2026).
Lead program · BLX-0871
Pan-AMPK activation drives cardiac hypertrophy → cardiac risk has halted every prior program → BLX-0871 cracks the code with α1γ3-containing precision.
Cardiac biomarker abnormalities at Phase 1 therapeutic exposures
Industry effort without an approved direct AMPK activator
α1γ3-containing precision activator into clinical trials
Source: Biolexis Phase 1 clinical data.
Leadership
Co-founder · Chairman
Serial entrepreneur with 25+ years in drug development, $2B+ in transaction value, and 18 clinical agents discovered.
Co-founder · Chief Scientific Officer
25+ years in biotech. Four companies founded, nine clinical agents discovered, and 100+ peer-reviewed publications.
President
Executive experienced in growth, transformation, and M&A. Private equity background and training. Former U.S. Army Infantry Officer.
Business Development
Leads partnerships and growth. Interdisciplinary background spanning chemical biology and corporate strategy.
VP, Clinical Affairs
Board certified in Internal Medicine. Oversees clinical programs across early- to late-stage development.
Director of Clinical Affairs
Ten years of experience in therapeutic promotion and clinical operations across biotech and academic environments.
Medical Consultant
Medical Oncologist with 30+ years of experience. Prior leadership roles at Newave, Halia, and Tolero.
Medical Consultant
40+ years in Emergency Medicine and Hospitalist care. Expert in clinical documentation and training.
News & updates
“The biology is settled. The next decade of metabolic medicine will be won on chemistry, route, and combination — exactly where we have spent our careers.”
— David J. Bearss, Co-founder & Chairman
Partner with us
We are selectively expanding our network of strategic partners and investors. Reach out and a member of the leadership team will respond directly.